News
The U.S. Court of Appeals for the First Circuit, in United States v. Regeneron, has joined the Sixth and Eighth Circuits in ...
Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...
The University of Copenhagen is excited to announce Repair Biotechnologies as a Tier 3 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in ...
John G Ullman & Associates Inc. made a hefty bet on Regeneron Pharmaceuticals, upping their stake by a whopping 94%, now ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord ...
Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a ...
Explore more
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...
Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.
A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for ...
We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...
Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...
In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results